Liege

• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• Extension Study to Assess Batoclimab in Participants with TED. Ended
  2024-512650-21-00 5 2023-12-13 Thyroid Eye Disease (TED)
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS Ended
  2023-503802-35-00 5 2023-11-29 Idiopathic or diabetic gastroparesis with moderate to severe nausea.
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• MK-8507 Extended Multiple Dose Study Ended
  2023-506697-12-00 3 2023-10-20 HIV-1 infection
• Open label, single-center, four-part registration pharmacokinetic study: Part I: Pilot 2-way cross-over randomized, comparative pharmacokine … Ended
  2023-507316-12-00 3 2023-10-20 Narcolepsy with cataplexy
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• MK-3508 Multiple Ascending Dose Study in Healthy Participants Ended
  2023-505821-15-00 3 2023-10-12 Respiratory syncytial virus infection
• A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in hea … Ended
  2023-505297-15-00 3 2023-10-10 Healthy female participants of childbearing potential.
• Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations ve … Ended
  2023-505769-98-00 3 2023-09-26 Narcolepsy
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie … Ended
  2022-502828-42-00 4 2023-09-01 Idiopathic Pulmonary Fibrosis
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitis Ended
  2022-501263-41-00 4 2023-08-10 Ulcerative Colitis
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• A clinical study of MK-6552 in healthy adults (MK-6552-002) Ended
  2023-504954-37-00 3 2023-07-07 Narcolepsy
• Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended
  2024-516321-31-00 4 2023-07-07 Type 3 spinal muscular atrophy
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended
  2024-512554-15-00 5 2023-06-21 COVID-19
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa

Showing 529–552 of 639 trials